Delta6PV Peptide for Beta-Cell Survival and T Cell Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases such as Type 1 Diabetes, Rheumatoid arthritis, Lupus, and Multiple Sclerosis primarily focus on symptom management rather than addressing the underlying autoimmune response, leading to incomplete recovery and long-term health issues.
Innovation Solution
Administration of the peptide Delta6PV (D6PV) to modulate the immune response, inhibit T cell expansion, and enhance beta-cell survival and insulin production, thereby delaying disease onset and improving glycemic control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current treatments for autoimmune diseases focus on symptom management, then patient comfort is improved, but the underlying autoimmune response is not addressed, leading to incomplete recovery
Solution Approach 1:
The patent extracts and targets the specific autoimmune mechanism (T cell expansion and beta-cell destruction) rather than managing general symptoms. The peptide D6PV specifically inhibits T cell proliferation and protects beta-cells, addressing the root cause of Type 1 Diabetes and other autoimmune conditions, thereby achieving complete recovery rather than just symptom relief
Solution Approach 2:
The patent applies preliminary action by preventing T cell expansion and beta-cell destruction before full disease manifestation occurs. The peptide D6PV is administered to delay disease onset and prevent autoimmune damage, rather than treating symptoms after they have developed, leading to more complete and effective recovery
2Device complexity
If current treatments focus on symptom management, then treatment simplicity is maintained, but long-term health issues persist
Solution Approach 1:
The patent extracts the specific autoimmune mechanism (T cell-mediated beta-cell destruction) and targets it directly with peptide D6PV. This specific targeting prevents long-term health issues by stopping the autoimmune process at its source, rather than managing symptoms that lead to progressive damage and chronic conditions
Solution Approach 2:
The patent changes the biochemical parameters of the immune system by introducing peptide D6PV, which modifies T cell proliferation rates and beta-cell survival. This biochemical intervention prevents long-term health deterioration by altering the fundamental immune response parameters, leading to sustained health improvement
3Reliability
If peptide D6PV is administered to inhibit T cell expansion, then autoimmune response is reduced, but the mechanism of action becomes more complex
Solution Approach 1:
The patent uses peptide D6PV as an intermediary substance that mediates between the immune system components. The peptide binds to and inhibits T cell proliferation while protecting beta-cells, serving as a molecular mediator that simplifies the complex immune interaction into a controllable therapeutic mechanism
Solution Approach 2:
The patent changes key immune parameters through peptide D6PV administration, specifically reducing T cell proliferation rates and increasing beta-cell survival. These parameter changes provide a straightforward mechanism of action that achieves reliable autoimmune control without excessive complexity in the therapeutic approach
4Productivity
If peptide D6PV is administered to enhance beta-cell survival, then insulin production increases, but the treatment protocol becomes more complex
Solution Approach 1:
The patent extracts and targets the specific function of beta-cell protection and insulin production enhancement. Peptide D6PV specifically protects beta-cells from autoimmune destruction and enhances their survival, thereby increasing insulin production through a targeted mechanism rather than a complex multi-component treatment protocol
Solution Approach 2:
The patent applies multi-functionality to peptide D6PV, which simultaneously inhibits T cell expansion, protects beta-cells, and enhances insulin production. This single peptide performs multiple functions that would otherwise require separate treatments, simplifying the overall treatment protocol while maintaining high productivity in insulin production
Data Source
AI summary
A method to prevent a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 Diabetes, Rheumatoid arthritis, Lupus, Sjogren's syndrome, Multiple Sclerosis, Grave's disease, Giant cell artereitis, Ankylosing spondylitis, and Guillian Barre Syndrome; and (2) monitoring the disease in the subject.